Evidence map›Paper›PMID 33376344›Full record

ArticleOncoTargets and therapy2020

Role of Lipids and Apolipoproteins in Predicting the Prognosis of Hepatocellular Carcinoma After Resection.

Xiao-Chun Ni, Yong Yi, Yi-Peng Fu, Xiao-Yan Cai, Gao Liu, Jin-Long Huang, Wei Gan, Jie Xu, Shuang-Jian Qiu

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Apolipoproteins: New players in cancers.Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Xiao-Chun NiShanghai Ninth People's Hospital, General Surgery, Shanghai, People's Republic of China.
Yong YiLiver Cancer Institute, Hepatic Surgery, Shanghai, People's Republic of China.ORCID 0000-0003-0847-2590
Yi-Peng FuObstetrics & Gynecology Hospital of Fudan University, Shanghai, People's Republic of China.
Xiao-Yan CaiShanghai Pudong Gongli Hospital, General Surgery, Shanghai, People's Republic of China.
Gao LiuLiver Cancer Institute, Hepatic Surgery, Shanghai, People's Republic of China.
Jin-Long HuangLiver Cancer Institute, Hepatic Surgery, Shanghai, People's Republic of China.
Wei GanLiver Cancer Institute, Hepatic Surgery, Shanghai, People's Republic of China.
Jie XuShanghai Ninth People's Hospital, Infection Disease, Shanghai, People's Republic of China.
Shuang-Jian QiuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China.
Shanghai Cancer Institute · CNShanghai Ninth People's Hospital · CNObstetrics and Gynecology Hospital of Fudan University · CNSecond Military Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo further clarify the association between abnormal levels of serum lipid components as the main features of dyslipidaemia and hepatocellular carcinoma, which remains unclear. PATIENTS AND

methodsWe examined the serum level of lipids and apolipoproteins pattern in 471 patients undergoing curative resection for HCC, 193 patients with chronic liver disease, and 104 patients with benign liver diseases. We performed uni- and multivariate analyses to evaluate the predictive roles of lipids and apolipoproteins for recurrence and survival of HCC in a training cohort of 242 patients and then validated in a cohort of 229 patients.

resultsThe majority circulating lipid and apolipoprotein levels such as ApoA1, HDL, and LDL in chronic liver disease and HCC were slightly significantly decreased as compared to those in benign lesion. But no significant differential expression patterns of lipids and apolipoproteins were observed between chronic liver hepatitis and HCC. Multivariable analysis identified ApoA1 as a key parameter related to recurrence and survival in both training and validation cohorts. Moreover, we further demonstrated that low ApoA1 was an independent prognostic factor of poor early recurrence in two cohorts.

conclusionAlthough the alterations of circulating lipids and apolipoproteins were observed in HCC, none of lipids or apolipoproteins could serve as a diagnostic marker. Serum ApoA1 merits consideration as a novel prognostic marker for patients with HCC undergoing surgery since it predicts early recurrence and survival, especially for early stage patients and may improve the prognostic stratification of patients for clinical management and promote HCC clinic outcomes.

Indexed as

apolipoproteinhepatocellular carcinomaprognosissurgery

Identifiers

PMID33376344
PMCPMC7756018
OpenAlexW3110658054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.